Skip to content
  • Sunday, 26 July 2026
  • 4:38 am
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Rubedo turns a senescence-targeting drug on precancerous skin, and sees an efficacy signal without the intense redness
Laboratory Automation & Robotics

Rubedo turns a senescence-targeting drug on precancerous skin, and sees an efficacy signal without the intense redness

Lana Keisha Jul 14, 2026 0

For millions worldwide, the diagnosis of actinic keratosis (AK) marks the beginning of a challenging journey to prevent skin cancer.…

Read More
Laboratory Automation & Robotics

Rubedo Life Sciences’ RLS-1496 Shows Promise in Treating Precancerous Skin Lesions with Minimal Irritation

Lana Keisha Jul 2, 2026 0

For millions worldwide grappling with actinic keratoses (AK), the rough, scaly patches of sun-damaged skin that are precursors to squamous…

Read More
Laboratory Automation & Robotics

Rubedo turns a senescence-targeting drug on precancerous skin, and sees an efficacy signal without the intense redness

Lana Keisha Jun 24, 2026 0

For millions worldwide, the diagnosis of actinic keratoses (AK) initiates a challenging journey to prevent the progression to skin cancer.…

Read More
Laboratory Automation & Robotics

Rubedo turns a senescence-targeting drug on precancerous skin, and sees an efficacy signal without the intense redness

Lana Keisha Jun 16, 2026 0

Rubedo Life Sciences, an AI-driven biotech startup focused on longevity, has announced positive preliminary results from its Phase 1b/2a study…

Read More
Laboratory Automation & Robotics

Rubedo turns a senescence-targeting drug on precancerous skin, and sees an efficacy signal without the intense redness

Lana Keisha Jun 2, 2026 0

For millions globally afflicted by actinic keratoses (AKs), the rough, scaly patches of sun-damaged skin that serve as precursors to…

Read More
Cellular Intelligence Licenses Novo Nordisk’s Parkinson’s Cell Therapy Program Following Company’s Strategic PivotChina Ascends to Global Clinical Trial Leadership as Immunology and Metabolic Diseases Emerge as Key Growth AreasGlioblastoma Research Reveals Cancer Reshapes Skull Bone and Disrupts Systemic Immune Response to Fuel Tumor GrowthGiant Peroxisomes in Seedling Development Reveal Universal Mechanism of Cellular Growth Control
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthLLMOps in 2026: The 10 Tools Every Team Must HaveJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals Plummet
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’sKing’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid DecompositionSanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
Lana Keisha Jul 25, 2026
Neuroscience & Brain Research
King’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286
Rifan Muazin Jul 25, 2026
Advanced Materials Science
Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid Decomposition
Nila Kartika Wati Jul 25, 2026
Pharmaceutical R&D
Sanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
Teuku Ryan Jul 25, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ